Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8375803 | 0.78 | THRB (0.51) | LMNAMAPTTHRBTSHRPTPN1 | |
| SCHEMBL17858732 | 0.78 | CYP2A6 (0.42) | CYP11B1CYP11B2TP53 | |
| SCHEMBL19736894 | 0.77 | MLLT1 (0.45) | LMNAMAPTTHRBTSHRPTPN1 | |
| SCHEMBL21083201 | 0.74 | S1PR1 (0.34) | PTPN1GABRA1GABRB2 | |
| SCHEMBL16775708 | 0.71 | LMNA (0.46) | LMNACYP11B1CYP11B2 | |
| SCHEMBL17773147 | 0.69 | TAAR1 (0.42) | LMNAMAPTTHRBTSHRTP53 | |
| SCHEMBL8378894 | 0.68 | CYP2A6 (0.48) | MAPTCYP11B1CYP11B2TP53 | |
| SCHEMBL19756421 | 0.67 | PRMT5 (0.40) | PRMT5WDR77CYP11B1CYP11B2 | |
| SCHEMBL725480 | 0.67 | PRMT5 (0.34) | LMNAPRMT5WDR77CYP11B1CYP11B2 | |
| SCHEMBL26244710 | 0.67 | CYP11B1 (0.33) | LMNAPRMT5WDR77CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | LMNA 4781/4885MAPT 3279/4885THRB 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.